Filtered By:
Drug: Zetia

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 236 results found since Jan 2013.

Farewell to the fasting cholesterol test?
At a recent meeting I offered a visitor lunch which she declined with obvious regret. She was hungry, and it was noon. But she was headed to her annual physical, and eating beforehand would mean returning another morning for a fasting cholesterol level. Most of us can relate to her annoyance, but thankfully this may soon be a thing of the past. Doctors have traditionally ordered cholesterol tests to be drawn after an overnight fast. But this requirement causes a significant burden on both sides of the health care equation. Most people hate to fast. Skipping meals is particularly difficult for active people, people with dia...
Source: New Harvard Health Information - June 16, 2016 Category: Consumer Health News Authors: Naomi D. L. Fisher, MD Tags: Health Heart Health Prevention Screening Tests and procedures Source Type: news

Reply Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful?
In response to Drs. Mascitelli and Goldstein, we previously reported in the primary publication of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) that there was no difference between ezetimibe plus simvastatin as compared with simvastatin alone with respect to cardiovascular death or all-cause mortality (1). Because the focus of the present paper is total cardiovascular events (2), we did not re-report all-cause mortality because the data were previously published, and a subject can only die once. This lack of difference was expected in IMPROVE-IT because prior trials of intensive-dose ve...
Source: Journal of the American College of Cardiology - June 21, 2016 Category: Cardiology Source Type: research

Ezetimibe-Statin Combination Therapy.
CONCLUSION: In high-risk patients with an acute coronary syndrome, combination therapy with ezetimibe and a statin lowered the risk of cardiovascular events in comparison to statin monotherapy. The risk of dying or suffering an adverse drug effect was similar in the two treatment groups. PMID: 27412989 [PubMed - in process]
Source: Deutsches Arzteblatt International - July 16, 2016 Category: Journals (General) Tags: Dtsch Arztebl Int Source Type: research

Merck Receives Complete Response Letter from the U.S. FDA for ZETIA ® (ezetimibe) and VYTORIN® (ezetimibe and simvastatin)
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding Merck ' s Supplemental New Drug Applications for ZETIA ® and VYTORIN® for the reduction of the risk of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, or need for revascularization) in patients with coronary heart disease. Language: English ...
Source: Merck.com - Product News - February 15, 2016 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news

Proprotein Convertase Subtilisin/Kexin Type 9 (PCKS9): Impact of PCKS9 on Major Adverse Cardiac and Cerebrovascular Events.
Authors: Akin M, Skripuletz T, Napp LC, Berliner D, Akin I, Haghikia A, Akin E, Bauersachs J Abstract Statins are the most widely prescribed drugs to reduce serum low density lipoprotein cholesterol (LDL-C) by inhibiting 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase. LDL-C reduction is associated with a decreased risk of atherosclerotic cardiovascular disease (ASCVD), including cardiovascular disease (CVD) and stroke. Statins reduce LDL-C by 30 to 40%, and the combination with other lipid-lowering agents such as ezetimibe leads to a further reduction by 20 to 25%. However, even the combination of these...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - July 31, 2016 Category: Cardiology Tags: Cardiovasc Hematol Agents Med Chem Source Type: research

Assessing Optimal Blood Pressure in Patients with Asymptomatic Aortic Valve Stenosis: The SEAS Study.
CONCLUSIONS: -Optimal BP seems to be systolic 130-139 mmHg and diastolic 70-90 mmHg in these patients with asymptomatic AS and no manifest atherosclerotic disease or diabetes. Clinical Trial Registration-http://www.clinicaltrials.gov; NCT00092677. PMID: 27486164 [PubMed - as supplied by publisher]
Source: Circulation - August 1, 2016 Category: Cardiology Authors: Nielsen OW, Sajadieh A, Sabbah M, Greve AM, Olsen MH, Boman K, Nienaber CA, Kesäniemi YA, Pedersen TR, Willenheimer R, Wachtell K Tags: Circulation Source Type: research

On-Treatment Analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)
Conclusions This analysis provides additional support for the efficacy and safety of adding Ez to S in this high-risk, post-ACS population.
Source: American Heart Journal - September 22, 2016 Category: Cardiology Source Type: research

ECS guidelines 2016 - dyslipidaemias.
Authors: Sinning D, Landmesser U Abstract Dyslipidaemia is a major cause of atherosclerotic cardiovascular disease and its progression towards clinical complications, such as acute coronary syndromes and stroke. In August 2016 the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) issued new joint guidelines for the management of dyslipidaemias. In these new guidelines, the concept of treating patients to a risk-based low-density lipoprotein (LDL) cholesterol target is reinforced. The task force considers LDL cholesterol as the primary target for dyslipidaemia treatment, whereas h...
Source: Herz - November 16, 2016 Category: Cardiology Tags: Herz Source Type: research

The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial
Conclusion The clinical benefit of adding ezetimibe to statin appears to be enhanced in patients with prior CABG, supporting the use of intensive lipid lowering therapy in these high-risk patients following ACS.
Source: European Heart Journal - January 12, 2017 Category: Cardiology Authors: Eisen, A., Cannon, C. P., Blazing, M. A., Bohula, E. A., Park, J.-G., Murphy, S. A., White, J. A., Giugliano, R. P., Braunwald, E., on behalf of the IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators Tags: Acute coronary syndromes Source Type: research

Addition of Ezetimibe to statins for patients at high cardiovascular risk: Systematic review of patient ‐important outcomes
Abstract Ezetimibe is widely used in combination with statins to reduce low‐density lipoprotein. We sought to examine the impact of ezetimibe when added to statins on patient‐important outcomes. Medline, EMBASE, CINAHL, and CENTRAL were searched through July, 2016. Randomized controlled trials (RCTs) of ezetimibe combined with statins versus statins alone that followed patients for at least 6 months and reported on at least one of all‐cause mortality, cardiovascular deaths, non‐fatal myocardial infarctions (MI), and non‐fatal strokes were included. Pairs of reviewers extracted study data and assessed risk of bia...
Source: Journal of Evaluation in Clinical Practice - January 15, 2017 Category: Journals (General) Authors: Yutong Fei, Gordon Henry Guyatt, Paul Elias Alexander, Regina El Dib, Reed A.C. Siemieniuk, Per Olav Vandvik, Mark E. Nunnally, Huda Gomaa, Rebecca L. Morgan, Arnav Agarwal, Ying Zhang, Neera Bhatnagar, Frederick A. Spencer Tags: SYSTEMATIC REVIEW Source Type: research

Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes
Publication date: Available online 26 January 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Eberhard Standl, Oliver Schnell, Darren K McGuire, Antonio Ceriello, Lars Rydén Cardiovascular outcome trials of antihyperglycaemic drugs and non-statin LDL-cholesterol-lowering drugs in patients with type 2 diabetes who have, or who are at high risk of, atherosclerotic cardiovascular disease have provided new evidence that has substantially affected the management of cardiovascular risk in these patients. On the basis of proven cardiovascular and renal benefit, the antihyperglycaemic drugs empagliflozin, lira...
Source: The Lancet Diabetes and Endocrinology - January 25, 2017 Category: Endocrinology Source Type: research

Lipid-lowering treatment modifications among patients with hyperlipidemia and a prior cardiovascular event: a US retrospective cohort study.
CONCLUSIONS: Real-world evidence indicates that few high-risk patients initiate therapy with high-intensity statins. More than 50% of patients underwent a rechallenge or switching. Despite high CVD risk profile, approximately 20% of patients permanently discontinued any LLT. Key limitations: Pharmacy claims do not provide information on whether patients who had a pharmacy fill actually took the medication as prescribed. It is unknown whether rechallenge was a simple delay in filling a prescription or an actual rechallenge of their index therapy. Reasons for treatment discontinuations or modifications were unavailable in cl...
Source: Current Medical Research and Opinion - March 10, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

Current status of lipid management in acute coronary syndrome.
Abstract The development of coronary revascularization has dramatically improved early cardiovascular outcomes in patients with acute coronary syndrome (ACS). However, patients who have experienced myocardial infarction (MI) are at high risk of recurrence of cardiovascular events compared with those who are healthy or have stable coronary artery disease. Acute coronary events induce further inflammatory responses and plaque vulnerability in either a coronary culprit or whole vessels. The majority of data have supported the importance of coronary risk management to prevent secondary events. Dyslipidemia is common a...
Source: Journal of Cardiology - March 18, 2017 Category: Cardiology Authors: Fujisue K, Tsujita K Tags: J Cardiol Source Type: research

Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Original Articles
Conclusions— Addition of ezetimibe to statin therapy in patients with a recent acute coronary syndrome leads to reductions in cardiovascular-related hospitalizations and associated costs, with the greatest cost offsets in high-risk patients. These cost reductions may completely offset the cost of the drug once ezetimibe becomes generic, and may lead to cost savings from the perspective of the healthcare system, if treatment with ezetimibe is targeted to high-risk patients. Clinical Trial Registration— URL: https://www.clinicaltrials.gov. Unique Identifier: NCT00202878
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2017 Category: Cardiology Authors: Pokharel, Y., Chinnakondepalli, K., Vilain, K., Wang, K., Mark, D. B., Davies, G., Blazing, M. A., Giugliano, R. P., Braunwald, E., Cannon, C. P., Cohen, D. J., Magnuson, E. A. Tags: Secondary Prevention, Cost-Effectiveness, Health Services Original Articles Source Type: research

The short term effect of atorvastatin plus ezetimibe therapy vs. atorvastatin monotherapy on clinical outcome in the acute coronary syndrome patients by gender.
CONCLUSIONS: The results of our study demonstrated that when added to statin therapy, EZE resulted in improved cardiovascular outcomes and the response to atorvastatin and EZE combination was similar for both men and women. PMID: 28553847 [PubMed - as supplied by publisher]
Source: Polish Heart Journal - May 29, 2017 Category: Cardiology Authors: Japaridze L, Sadunishvili M Tags: Kardiol Pol Source Type: research